Department of Radiation Oncology, Center for Molecular Imaging and Experimental Radiotherapy (IMRE), Université Catholique de Louvain, Belgium.
Radiother Oncol. 2010 May;95(2):209-17. doi: 10.1016/j.radonc.2010.03.007. Epub 2010 Apr 10.
Anatomic changes occur during radiation therapy (RT) for head and neck (H&N) tumors. This study aims at quantifying the volumetric and positional changes of gross tumor volumes (GTV), clinical target volumes (CTV), and organs at risk (OAR). Anatomic (CT) and functional (FDG-PET) imaging were used for the delineation of the GTVs.
Ten patients with H&N tumors treated by chemo-RT were used. Contrast-enhanced CT and FDG-PET were acquired prior and during RT following delivery of mean doses of 14.2, 24.5, 35.0, and 44.9 Gy. CT-based GTVs were manually delineated, and PET-based GTVs were segmented using a gradient-based segmentation method. Pre-treatment prophylactic dose CTVs were manually delineated on the pre-treatment CT using consistent and reproducible guidelines. Per-treatment prophylactic CTVs were obtained with an automatic re-contouring method based on deformable registration. For the therapeutic dose CTVs, a 5 mm margin was applied around the corresponding GTVs. OARs such as the parotid glands and the submandibular glands were manually delineated on the pre-treatment CT. OARs on the per-treatment CT were automatically delineated using the method used for prophylactic CTVs. The mean slopes of the relative change in volume over time and the mean displacements of the center of mass after 44.9 Gy were calculated for each volume.
Regarding volumetric changes, CT-based and PET-based primary tumor GTVs decreased at a mean rate of 3.2% and 3.9%/treatment day (td), respectively; nodal GTVs decreased at a mean rate of 2.2%/td. This led to a corresponding decrease of the CT-based and PET-based therapeutic CTVs by 2.4% and 2.5%/td, respectively. CT- and PET-based prophylactic tumor CTVs decreased by an average of 0.7% and 0.5%/td, respectively. No difference in volume shrinkage was observed between CT- and PET-based volumes. The ipsilateral and contralateral parotid glands showed a mean decrease of 0.9% and 1.0%/td, respectively. The ipsilateral and contralateral submandibular glands shrank at a mean rate of 1.5% and 1.3%/td, respectively. Regarding positional changes, CT-based GTVs showed a lateral shift of 1.3 mm, PET-based GTVs a posterior shift of 3.4mm and the nodal GTVs a medial shift of 1.0 mm, translating into parallel shifts of the therapeutic CTVs. The ipsilateral prophylactic nodal CTV shifted medially by 1.8 mm. The ipsilateral parotid gland shifted medially by 3.4 mm. The ipsilateral submandibular gland showed a medial shift of 1.7 mm and a superior shift of 2.7 mm. The contralateral submandibular gland only showed a superior shift of 1.7 mm.
Volumetric and positional changes in TVs and OARs were observed during concomitant chemo-RT suggesting that adaptive strategies, where patients are re-imaged and possibly re-planned during treatment, are worth evaluating.
头颈部(H&N)肿瘤在放射治疗(RT)过程中会发生解剖学变化。本研究旨在量化大体肿瘤体积(GTV)、临床靶区(CTV)和危及器官(OAR)的体积和位置变化。使用解剖学(CT)和功能(FDG-PET)成像来勾画 GTVs。
10 例接受化疗联合 RT 的 H&N 肿瘤患者入组。在给予 14.2、24.5、35.0 和 44.9 Gy 平均剂量的 RT 前后,采集增强 CT 和 FDG-PET。手动勾画 CT 上的 GTVs,并使用基于梯度的分割方法对 FDG-PET 上的 GTVs 进行分割。在治疗前 CT 上使用一致和可重复的指南手动勾画预防性 CTVs。通过基于变形配准的自动重新勾画方法获得治疗性 CTVs。对于治疗性 CTV,在相应的 GTV 周围应用 5mm 边界。在治疗前 CT 上手动勾画腮腺和颌下腺等 OARs。在治疗前 CT 上使用用于勾画预防性 CTV 的方法自动勾画 OARs。计算每个体积的时间相关体积相对变化的平均斜率和 44.9 Gy 后质量中心的平均位移。
关于体积变化,CT 基和 PET 基原发肿瘤 GTV 分别以 3.2%和 3.9%/治疗日(td)的平均速率下降;淋巴结 GTV 以 2.2%/td 的平均速率下降。这导致 CT 基和 PET 基治疗性 CTV 分别以 2.4%和 2.5%/td 的相应下降。CT 基和 PET 基预防性肿瘤 CTV 分别平均减少 0.7%和 0.5%/td。CT 基和 PET 基体积的体积收缩没有差异。同侧和对侧腮腺分别以 0.9%和 1.0%/td 的平均速率下降。同侧和对侧颌下腺分别以 1.5%和 1.3%/td 的平均速率收缩。关于位置变化,CT 基 GTV 显示外侧移位 1.3mm,PET 基 GTV 显示后向移位 3.4mm,淋巴结 GTV 显示内侧移位 1.0mm,导致治疗性 CTV 发生平行移位。同侧预防性淋巴结 CTV 向内侧移位 1.8mm。同侧腮腺向内侧移位 3.4mm。同侧颌下腺向内侧移位 1.7mm,向上移位 2.7mm。对侧颌下腺仅向上移位 1.7mm。
在同期放化疗过程中观察到 GTVs 和 OARs 的体积和位置变化,提示自适应策略值得评估,即在治疗过程中对患者进行重新成像和可能的重新计划。